Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target

Guggenheim analyst Michael Schmidt has reiterated a Buy rating on Zentalis Pharma (NASDAQ: ZNTL) and has maintained a price target of $6 for the stock. This endorsement suggests continued confidence in the company's performance and potential for growth.